Login to Your Account



Acorda Reports Spinal Cord Injury Miss, Positive Trends Seen In MS

By Karen Pihl-Carey


Thursday, April 15, 2004
It was a mixed day for Acorda Therapeutics Inc., which said Fampridine-SR missed its endpoints in two pivotal Phase III trials in spinal cord injury (SCI), but also said the drug showed positive trends in a Phase II multiple sclerosis (MS) trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription